[2]Roche to present firstclinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO.Retrieved 2020-05-14, from网页链接 [3] Roche Pharma Research and Early Development (pRED) Early Drug Development Investor Relations Event 2019. Retrieved November 11, 2019, from网页链接...
Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving ...
14CROSSWALK-c (NCT05075824) ClinicalTrials.gov. [Internet; cited June 2024]. Available at:https://clinicaltrials.gov/ct2/show/NCT05075824. Roche Global Media Relations Phone: +41 61 688 8888 / e-mail:media.relations@roche.com Roche Inv...
Investor Relations, UCB T+32.2.559.9588, isabelle.ghellynck@ucb.com Forward looking statements UCB This press release may contain forward-looking statements including, without limitation, statements containing the words “believes”, “anticipates”, “expects”...
declaration is terminated or authorization is revoked sooner. RocheGlobal Media RelationsPhone: +41 61 688 8888 / e-mail:media.relations@roche.com RocheInvestor Relations Investor RelationsNorth America Loren KalmPhone: +1 650 225 3217 e-mail:...
Roche Holding AG (OTCQX:RHHBY) Q2 2023 Earnings Conference Call July 27, 2023 8:00 AM ETCompany ParticipantsBruno Eschli - Head, Investor RelationsThomas...
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an exclusive, global license for the Company’s newly engineered double-stranded DNA (dsDNA) ligase for next-generation se
For more information, please visitwww.roche.com. All trademarks used or mentioned in this release are protected by law. Roche Global Media Relations Phone: +41 61 688 8888 / e-mail:media.relations@ro...
pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combin...
Investor Relations, UCB T+32.2.559.9588, isabelle.ghellynck@ucb.com Forward looking statements UCB This press release may contain forward-looking statements including, without limitation, statements containing the words "believes", "anticipates", "expec...